Phosphodiesterase 4D Inhibitors Limit Prostate Cancer Growth Potential

Overview

Journal Mol Cancer Res

Specialty Cell Biology

Date 2014 Aug 24

PMID 25149359

Citations 28

Authors

Ginny L Powers

Kimberly D P Hammer

Maribella Domenech

Katsiaryna Frantskevich

Rita L Malinowski

Wade Bushman

David J Beebe

Paul C Marker

Affiliations

Soon will be listed here.

Abstract

Unlabelled: Phosphodiesterase 4D (PDE4D) has recently been implicated as a proliferation-promoting factor in prostate cancer and is overexpressed in human prostate carcinoma. However, the effects of PDE4D inhibition using pharmacologic inhibitors have not been examined in prostate cancer. These studies examined the effects of selective PDE4D inhibitors, NVP-ABE171 and cilomilast, as anti-prostate cancer therapies in both in vitro and in vivo models. The effects of PDE4D inhibitors on pathways that are critical in prostate cancer and/or downstream of cyclic AMP (cAMP) were examined. Both NVP-ABE171 and cilomilast decreased cell growth. In vitro, PDE4D inhibitors lead to decreased signaling of the sonic hedgehog (SHH), androgen receptor (AR), and MAPK pathways, but growth inhibition was best correlated to the SHH pathway. PDE4D inhibition also reduced proliferation of epithelial cells induced by paracrine signaling from cocultured stromal cells that had activated hedgehog signaling. In addition, PDE4D inhibitors decreased the weight of the prostate in wild-type mice. Prostate cancer xenografts grown in nude mice that were treated with cilomilast or NVP-ABE171 had decreased wet weight and increased apoptosis compared with vehicle-treated controls. These studies suggest the pharmacologic inhibition of PDE4D using small-molecule inhibitors is an effective option for prostate cancer therapy.

Implications: PDE4D inhibitors decrease the growth of prostate cancer cells in vivo and in vitro, and PDE4D inhibition has therapeutic potential in prostate cancer.

Citing Articles

PDE4D drives rewiring of the MAPK pathway in BRAF-mutated melanoma resistant to MAPK inhibitors.

Delyon J, Becherirat S, Roger A, Bernard-Cacciarella M, Reger De Moura C, Louveau B Cell Commun Signal. 2024; 22(1):559.

PMID: 39574163 PMC: 11580363. DOI: 10.1186/s12964-024-01941-y.

Expression Pattern of PDE4B, PDE4D, and SFRP5 Markers in Colorectal Cancer.

Bevanda M, Kelam N, Racetin A, Filipovic N, Bevanda Glibo D, Bevanda I Medicina (Kaunas). 2024; 60(8).

PMID: 39202484 PMC: 11356070. DOI: 10.3390/medicina60081202.

cAMP-PKA/EPAC signaling and cancer: the interplay in tumor microenvironment.

Zhang H, Liu Y, Liu J, Chen J, Wang J, Hua H J Hematol Oncol. 2024; 17(1):5.

PMID: 38233872 PMC: 10792844. DOI: 10.1186/s13045-024-01524-x.

Inhibition of phosphodiesterase 4D suppresses mTORC1 signaling and pancreatic cancer growth.

Jeong M, Urquhart G, Lewis C, Chi Z, Jewell J JCI Insight. 2023; 8(13).

PMID: 37427586 PMC: 10371348. DOI: 10.1172/jci.insight.158098.

Genome-wide interrogation of structural variation reveals novel African-specific prostate cancer oncogenic drivers.

Gong T, Jaratlerdsiri W, Jiang J, Willet C, Chew T, Patrick S Genome Med. 2022; 14(1):100.

PMID: 36045381 PMC: 9434886. DOI: 10.1186/s13073-022-01096-w.

References

Rabe K . Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Br J Pharmacol. 2011; 163(1):53-67. PMC: 3085868. DOI: 10.1111/j.1476-5381.2011.01218.x. View

Sheng T, Li C, Zhang X, Chi S, He N, Chen K . Activation of the hedgehog pathway in advanced prostate cancer. Mol Cancer. 2004; 3:29. PMC: 524523. DOI: 10.1186/1476-4598-3-29. View

Wang B, Fallon J, Beachy P . Hedgehog-regulated processing of Gli3 produces an anterior/posterior repressor gradient in the developing vertebrate limb. Cell. 2000; 100(4):423-34. DOI: 10.1016/s0092-8674(00)80678-9. View

Domenech M, Bjerregaard R, Bushman W, Beebe D . Hedgehog signaling in myofibroblasts directly promotes prostate tumor cell growth. Integr Biol (Camb). 2012; 4(2):142-52. PMC: 3335396. DOI: 10.1039/c1ib00104c. View

MacKenzie S, Houslay M . Action of rolipram on specific PDE4 cAMP phosphodiesterase isoforms and on the phosphorylation of cAMP-response-element-binding protein (CREB) and p38 mitogen-activated protein (MAP) kinase in U937 monocytic cells. Biochem J. 2000; 347(Pt 2):571-8. PMC: 1220991. DOI: 10.1042/0264-6021:3470571. View

Azoulay S, Terry S, Chimingqi M, Sirab N, Faucon H, Gil Diez de Medina S . Comparative expression of Hedgehog ligands at different stages of prostate carcinoma progression. J Pathol. 2008; 216(4):460-70. DOI: 10.1002/path.2427. View

Peng Y, Levine C, Zahid S, Wilson E, Joyner A . Sonic hedgehog signals to multiple prostate stromal stem cells that replenish distinct stromal subtypes during regeneration. Proc Natl Acad Sci U S A. 2013; 110(51):20611-6. PMC: 3870668. DOI: 10.1073/pnas.1315729110. View

Uckert S, Oelke M, Stief C, Andersson K, Jonas U, Hedlund P . Immunohistochemical distribution of cAMP- and cGMP-phosphodiesterase (PDE) isoenzymes in the human prostate. Eur Urol. 2006; 49(4):740-5. DOI: 10.1016/j.eururo.2005.12.050. View

Thalmann G, Sikes R, Wu T, Degeorges A, Chang S, Ozen M . LNCaP progression model of human prostate cancer: androgen-independence and osseous metastasis. Prostate. 2000; 44(2):91-103 Jul 1;44(2). DOI: 10.1002/1097-0045(20000701)44:2<91::aid-pros1>3.0.co;2-l. View

10.

Buresh-Stiemke R, Malinowski R, Keil K, Vezina C, Oosterhof A, van Kuppevelt T . Distinct expression patterns of Sulf1 and Hs6st1 spatially regulate heparan sulfate sulfation during prostate development. Dev Dyn. 2012; 241(12):2005-13. PMC: 3677568. DOI: 10.1002/dvdy.23886. View

11.

Dong H, Zitt C, Auriga C, Hatzelmann A, Epstein P . Inhibition of PDE3, PDE4 and PDE7 potentiates glucocorticoid-induced apoptosis and overcomes glucocorticoid resistance in CEM T leukemic cells. Biochem Pharmacol. 2009; 79(3):321-9. DOI: 10.1016/j.bcp.2009.09.001. View

12.

Edwards H, Christian F, Baillie G . cAMP: novel concepts in compartmentalised signalling. Semin Cell Dev Biol. 2011; 23(2):181-90. DOI: 10.1016/j.semcdb.2011.09.005. View

13.

Ji Z, Mei F, Johnson B, Thompson E, Cheng X . Protein kinase A, not Epac, suppresses hedgehog activity and regulates glucocorticoid sensitivity in acute lymphoblastic leukemia cells. J Biol Chem. 2007; 282(52):37370-7. DOI: 10.1074/jbc.M703697200. View

14.

Hammerschmidt M, Bitgood M, McMahon A . Protein kinase A is a common negative regulator of Hedgehog signaling in the vertebrate embryo. Genes Dev. 1996; 10(6):647-58. DOI: 10.1101/gad.10.6.647. View

15.

Sugimura Y, Cunha G, Donjacour A . Morphological and histological study of castration-induced degeneration and androgen-induced regeneration in the mouse prostate. Biol Reprod. 1986; 34(5):973-83. DOI: 10.1095/biolreprod34.5.973. View

16.

Chandrasekaran A, Toh K, Low S, Tay S, Brenner S, Goh D . Identification and characterization of novel mouse PDE4D isoforms: molecular cloning, subcellular distribution and detection of isoform-specific intracellular localization signals. Cell Signal. 2007; 20(1):139-53. DOI: 10.1016/j.cellsig.2007.10.003. View

17.

Zhang J, Lipinski R, Shaw A, Gipp J, Bushman W . Lack of demonstrable autocrine hedgehog signaling in human prostate cancer cell lines. J Urol. 2007; 177(3):1179-85. DOI: 10.1016/j.juro.2006.10.032. View

18.

Sekulic A, Migden M, Oro A, Dirix L, Lewis K, Hainsworth J . Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med. 2012; 366(23):2171-9. PMC: 5278761. DOI: 10.1056/NEJMoa1113713. View

19.

Giembycz M . An update and appraisal of the cilomilast Phase III clinical development programme for chronic obstructive pulmonary disease. Br J Clin Pharmacol. 2006; 62(2):138-52. PMC: 1885082. DOI: 10.1111/j.1365-2125.2006.02640.x. View

20.

Chang H, Chen B, Wu C, Tsao Z, Chen Y, Chang C . Hedgehog overexpression leads to the formation of prostate cancer stem cells with metastatic property irrespective of androgen receptor expression in the mouse model. J Biomed Sci. 2011; 18:6. PMC: 3025942. DOI: 10.1186/1423-0127-18-6. View